am -
pm ET

Let’s Work Together

Alnylam Assist™ knows how important one on-one interactions are, which is why we have Case Managers and Patient Education Liaisons (PELs) to provide product education, tools to connect with the community, and resources that can help you during treatment.

Alnylam Assist® Case Managers

Alnylam Case Managers

Once you and your doctor choose to start treatment with AMVUTTRA® (vutrisiran), you will be partnered with a Case Manager. Case Managers are trained professionals whose expertise is in helping patients get started on treatment and providing product support. They will tailor their method of communication to what works best for you.

A Case Manager will help you understand your insurance coverage benefits and verify them for you. They can also inform you about options for financial support that you may be eligible for as well as provide you with educational resources. In addition, Case Managers can connect you with a PEL.

Alnylam Assist® Case Manager Natalie

Meet Your Local Case ManagerRead Natalie's Bio ›

Alnylam Assist® Patient Education Liaisons

Alnylam Patient Education Liaisons

A Case Manager also can help connect you with a Patient Education Liaison (PEL). PELs have backgrounds in nursing, and are experienced in educating people and family members about hATTR amyloidosis. Your PEL can help you in a variety of ways, including:

Supporting you with disease education

Providing you with product information

Connecting you to additional resources

Answering questions about treatment with AMVUTTRA

In addition, PELs help facilitate educational events about hATTR Amyloidosis in communities around the United States. Talk to a Case Manager about finding an event in your area, or request a conversation with a PEL. Talk to a PEL ›

The purpose of Alnylam Patient Education Liaisons (PELs) is to provide education to patients, their families, and caregivers

PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team

PELs do not provide medical care or advice

All diagnosis and treatment decisions should be made by you and your doctor

What additional resources does Alnylam Assist™ offer?

Downloadable educational materials about hATTR amyloidosis and treatment with AMVUTTRA, as well as links to advocacy groups that connect patients to the hATTR amyloidosis community. Find additional resources ›

Alnylam Assist® - Questions Icon

Find answers to other

Frequently Asked Questions ›

Alnylam Assist® get started icon

See How to Get Started

Once you and your doctor decide to begin treatment with AMVUTTRA, we'll work with your healthcare team to start the process.

How to Get Started

Alnylam Assist® Case Manager Natalie

Call Natalie


Monday - Friday,
8am - 6pm

Alylam Separator Triangles


What are the most important things I should know about AMVUTTRA® (vutrisiran)?

AMVUTTRA can cause:

Low Vitamin A Levels

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA are pain in the joints (arthralgia), shortness of breath (dyspnea), and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.


What is AMVUTTRA® (vutrisiran)?

AMVUTTRA is a prescription medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin‑mediated amyloidosis (hATTR amyloidosis). AMVUTTRA is used in adults only.

For additional information about AMVUTTRA, please see the full Prescribing Information.